Please wait



Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox not checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)


X0202 SCHEDULE 13D 0001232621 XXXXXXXX LIVE Ordinary Shares par value NIS 5.00 per share 06/24/2026 false 0001643303 63008G203 Nano Dimension Ltd. 60 Tower Road Waltham MA 02451 Kevin Tang 858-200-3830 4747 Executive Drive Suite 210 San Diego CA 92121 0001232621 N TANG CAPITAL MANAGEMENT, LLC WC N DE 0.00 14292813.00 0.00 14292813.00 14292813.00 N 6.8 OO Tang Capital Management, LLC ("TCM") beneficially owns 14,292,813 of the Issuer's American Depository Shares ("ADSs") which each represent one Ordinary Share of the Issuer. TCM shares voting and dispositive power over such shares with Tang Capital Partners, LP ("TCP"), Tang Capital Partners International, LP ("TCPI"), Tang Capital Partners III, Inc. ("TCP III"), Tang Capital Partners IV, Inc. ("TCP IV") and Kevin Tang. The percentages used herein are based on 210,506,899 Ordinary Shares outstanding as of June 23, 2026, as set forth in the Issuer's Schedule 14A filed on Form DEFC14A with the Securities and Exchange Commission on June 25, 2026. 0001178579 N KEVIN TANG WC N X1 0.00 14292813.00 0.00 14292813.00 14292813.00 N 6.8 IN Kevin Tang beneficially owns 14,292,813 of the Issuer's ADSs which each represent one Ordinary Share of the Issuer. Kevin Tang shares voting and dispositive power over such shares with TCP, TCPI, TCP III, TCP IV and TCM. 0001191935 N TANG CAPITAL PARTNERS, LP WC N DE 0.00 3275445.00 0.00 3275445.00 3275445.00 N 1.6 PN TCP beneficially owns 3,275,445 of the Issuer's ADSs which each represent one Ordinary Share of the Issuer. TCP shares voting and dispositive power over such shares with TCM and Kevin Tang. 0002064011 N TANG CAPITAL PARTNERS INTERNATIONAL, LP WC N DE 0.00 4466490.00 0.00 4466490.00 4466490.00 N 2.0 PN TCPI beneficially owns 4,466,490 of the Issuer's ADSs which each represent one Ordinary Share of the Issuer. TCPI shares voting and dispositive power over such shares with TCM and Kevin Tang. 0002036763 N TANG CAPITAL PARTNERS III, INC WC N NV 0.00 3275445.00 0.00 3275445.00 3275445.00 N 1.6 CO TCP III beneficially owns 3,275,445 of the Issuer's ADSs which each represent one Ordinary Share of the Issuer. TCP III shares voting and dispositive power over such shares with TCM and Kevin Tang. 0002036770 N TANG CAPITAL PARTNERS IV, INC WC N NV 0.00 3275433.00 0.00 3275433.00 3275433.00 N 1.6 CO TCP IV beneficially owns 3,275,433 of the Issuer's ADSs which each represent one Ordinary Share of the Issuer. TCP IV shares voting and dispositive power over such shares with TCM and Kevin Tang. 0001970065 N CONCENTRA BIOSCIENCES, LLC WC N DE 0.00 0.00 0.00 0.00 0.00 N 0 OO Ordinary Shares par value NIS 5.00 per share Nano Dimension Ltd. 60 Tower Road Waltham MA 02451 This Statement is filed by TCM, a Delaware limited liability company that is the general partner of TCP and TCPI; Kevin Tang, a United States citizen; TCP, a Delaware limited partnership engaged in capital management; TCPI, a Delaware limited partnership engaged in capital management; TCP III, a Nevada corporation that is indirectly wholly owned by TCP; TCP IV, a Nevada corporation that is indirectly wholly owned by TCP; and Concentra Biosciences, LLC, a Delaware limited liability company controlled by TCP ("Concentra" and, collectively with TCM, Kevin Tang, TCP, TCPI, TCP III and TCP IV, the "Reporting Persons"). The address of TCM, Kevin Tang, TCP, TCPI and Concentra is 4747 Executive Drive, Suite 210, San Diego, CA 92121. The address of TCP III and TCP IV is 400 S. 4th Street, 3rd Floor, Las Vegas, NV 89101. Kevin Tang is the manager of TCM. Kevin Tang is the sole director and Chief Executive Officer of TCP III and TCP IV. Kevin Tang is the Chief Executive Officer of Concentra. During the past five years, none of the Reporting Persons have been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). During the past five years, none of the Reporting Persons have been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. See Item 2(a) above. The Ordinary Shares were acquired with approximately $19.5 million of working capital set aside by TCP, TCPI, TCP III and TCP IV for the general purpose of investing. TCP, TCPI, TCP III and TCP IV maintain commingled margin accounts with various financial institutions, which may extend margin credit to TCP, TCPI, TCP III, and TCP IV as and when required, to open or carry positions in the margin accounts, subject to applicable federal margin regulations, stock exchange rules and credit policies. In such instances, the positions held in the margin accounts are pledged as collateral security for the repayment of debit balances in the accounts. The margin accounts may from time to time have debit balances. Since multiple different securities are held in the margin accounts, it is not possible to determine the amounts, if any, of margin used to purchase the Ordinary Shares reported herein. The Reporting Persons purchased the Ordinary Shares reported hereunder for investment purposes, and such purchases were made in the Reporting Persons' ordinary course of business. As with their other investments, the Reporting Persons continuously evaluate the Issuer, including, but not limited to, its businesses, operations and prospects. In light of that ongoing evaluation, on June 30, 2026, TCM sent a merger proposal to the Issuer outlining the principal terms on which it would effect a merger between the Issuer and an affiliate of the Reporting Persons (see Exhibit 2). The merger proposal provides that it is subject to limited confirmatory diligence, as well as the execution of a definitive merger agreement. The Reporting Persons intend to engage in discussions with the Issuer and its representatives regarding the merger proposal and to enter into negotiations with the Issuer with respect thereto. There can be no certainty as to whether discussions will occur, or, if they do, the outcome of such discussions. While the Reporting Persons may seek to enter into a confidentiality agreement with the Issuer and intend to pursue the merger proposal, in connection with their investment in the Issuer, the Reporting Persons may, subject to applicable law and regulation, modify their ownership of the Ordinary Shares, including acquiring additional Ordinary Shares or disposing of some or all of the Ordinary Shares beneficially owned by them. Such actions may be based on the Reporting Persons' assessment of the Issuer's operations and prospects, prevailing market conditions or other investment considerations. The Reporting Persons may at any time reconsider and/or change their plans or proposals relating to the foregoing. The information set forth in the cover pages of this Schedule 13D is hereby incorporated by reference into this Item 5. As of the date hereof the Reporting Persons beneficially own an aggregate of 14,292,813 shares of the Issuer's Ordinary Shares, representing 6.8% of the outstanding shares. See item 5(a) above. Schedule A attached hereto as Exhibit 3 describes all transactions in the Issuer's Ordinary Shares that were effected during the past 60 days by the Reporting Persons. No person other than a Reporting Person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, Ordinary Shares beneficially owned by the Reporting Persons. Not applicable To the best of the knowledge of the Reporting Persons, there are no contracts, arrangements, understandings or relationships (legal or otherwise) among the Reporting Persons or between the Reporting Persons and any person with respect to any securities of the Issuer, including but not limited to transfer or voting of any of the securities, finder's fees, joint ventures, loan or option arrangements, puts or calls, guarantees of profits, division of profits or loss, or the giving or withholding of proxies. Exhibit 1: Joint Filing Agreement by and among the Reporting Persons. Exhibit 2: Merger Proposal, dated June 30, 2026, sent from TCM to the Issuer. Exhibit 3: Schedule A: Transactions during the past 60 days. TANG CAPITAL MANAGEMENT, LLC /s/ Kevin Tang Manager 06/30/2026 KEVIN TANG /s/ Kevin Tang Self 06/30/2026 TANG CAPITAL PARTNERS, LP /s/ Kevin Tang Manager, Tang Capital Management, LLC, General Partner 06/30/2026 TANG CAPITAL PARTNERS INTERNATIONAL, LP /s/ Kevin Tang Manager, Tang Capital Management, LLC, General Partner 06/30/2026 TANG CAPITAL PARTNERS III, INC /s/ Kevin Tang Chief Executive Officer 06/30/2026 TANG CAPITAL PARTNERS IV, INC /s/ Kevin Tang Chief Executive Officer 06/30/2026 CONCENTRA BIOSCIENCES, LLC /s/ Kevin Tang Chief Executive Officer 06/30/2026